Dr Patricia Lawman | Chief Executive Officer
Morphogenesis I.N.C.

Dr Patricia Lawman, Chief Executive Officer, Morphogenesis I.N.C.

Patricia Lawman, PhD, co-founder and CEO of Morphogenesis, Inc. since 2003, received her graduate education in molecular biology and immunology from the College of Medicine at the University of Florida where she also served as a Postdoctoral Fellow in Pediatric Hematology and Oncology. Prior to founding Morphogenesis, Dr. Lawman was Division Director of Cancer Molecular Biology at the Walt Disney Memorial Cancer Institute. She has held adjunct faculty positions at the University of Central Florida and the University of South Florida and has served on numerous committees at local/state/federal levels. Dr. Lawman holds over 30 patents and as many publications and has received multiple business and scientific honors. Morphogenesis is an emerging clinical stage cell and gene therapy company. The company is testing its off-the-shelf, personalized cancer immunotherapy in two ongoing human clinical trials with a Phase II skin cancer basket trial planned for 2020.

Appearances:



Pre-congress Workshops, April 6 @ 10:00

WORKSHOP B (FULL DAY): ANIMAL HEALTH

AM: SCIENTIFIC ADVANCEMENTS IN THE COMPANION ANIMAL CANCER VACCINE SPACEWorkshop Leader: Philip J. Bergman
  • Overcoming current limitations in selecting immunogenic neoantigens
  • Bridging the gap between human and animal cancer: translational studies of a polyvalent cancer preventative vaccine
  • Personalized autologous cancer vaccine for cats & dogs
  • Development of an animal health vaccine using gene-based checkpoint inhibitors
  • The safety of an adjuvanted autologous cancer vaccine platform in canine cancer patients
  • From treating veterinary cancers to launching a first-in-human clinical trial
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates